B-Cell Lymphoma Clinical Trials

• Age no less than 18, no gender limit;

• Newly diagnosed high-risk Large B-cell Lymphoma, which was defined by the following criteria: (1) DLBCL not otherwise specified with an IPI score ≥3 at diagnosis, (2) high grade B-cell lymphoma (HGBL) with gene rearrangement of MYC and BCL2 and/or BCL6, (3) HGBL not otherwise specified;

• Confirmed CD19 and CD20 postive expressions in lymphoma cells

• ECOG score 0-2;

• Total bilirubin ≤ 51 umol/L, ALT and AST ≤ 3 times of upper limit of normal, creatinine ≤ 176.8 umol/L;

• Echocardiogram shows left ventricular ejection fraction (LVEF) ≥50%;

• No active infection in the lungs, blood oxygen saturation in indoor air is ≥ 92%;

• Estimated survival time ≥ 3 months;

• Patients or their legal guardians volunteer to participate in the study and sign the informed consent.